Caroline Palomeque
Stock Analyst at Maxim Group
(1.22)
# 3,745
Out of 5,150 analysts
10
Total ratings
44.44%
Success rate
-2.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $1.57 | +411.18% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $28.27 | +108.70% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $263.80 | -41.62% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $69.40 | -16.43% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $239.22 | -30.61% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $20.02 | +94.81% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $8.69 | +601.96% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $4.69 | +752.88% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $1.57
Upside: +411.18%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $28.27
Upside: +108.70%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $263.80
Upside: -41.62%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $69.40
Upside: -16.43%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $239.22
Upside: -30.61%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $20.02
Upside: +94.81%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $8.69
Upside: +601.96%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $4.69
Upside: +752.88%